The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease

被引：41

作者：

Ewaschuk J.B. ^{[1
]}

Tejpar Q.Z. ^{[1
]}

Soo I. ^{[1
]}

Madsen K.L. ^{[1
]}

Fedorak R.N. ^{[1
]}

机构：

[1] Division of Gastroenterology, Zeidler Family Gastrointestinal Health and Research Centre, Edmonton, AB T6G 2C8

来源：

Current Gastroenterology Reports | 2006年 / 8卷 / 6期

关键词：

Ulcerative Colitis; Metronidazole; Mesalazine; Rifaximin; Mesalamine;

D O I：

10.1007/s11894-006-0039-z

中图分类号：

学科分类号：

摘要：

Abundant evidence indicates that the intestinal microflora have a role in the pathogenesis of inflammatory bowel disease (IBD). The composition of the gut microflora is altered in IBD patients with increased "pathogenic" bacteria and decreased bifidobacteria and lactobacilli. In light of this dysbiosis, various methods have been examined to alter the composition of the intestinal microflora, including the administration of antibiotics and introduction of probiotic species. This article summarizes studies evaluating the efficacy of antibiotics and probiotics in the induction and maintenance of remission of ulcerative colitis, Crohn's disease, and pouchitis. Copyright © 2006 by Current Science Inc.

引用

页码：486 / 498

页数：12

共 56 条

[1]

Rath H.C., Herfarth H.H., Ikeda J.S., Et al., Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats, J Clin Invest, 98, pp. 945-953, (1996)

[2]

Sellon R.K., Tonkonogy S., Schultz M., Et al., Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice, Infect Immun, 66, pp. 5224-5231, (1998)

[3]

Duchmann R., Kaiser I., Hermann E., Et al., Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD), Clin Exp Immunol, 102, pp. 448-455, (1995)

[4]

Swidsinski A., Ladhoff A., Pernthaler A., Et al., Mucosal flora in inflammatory bowel disease, Gastroenterology, 122, pp. 44-54, (2002)

[5]

Kleessen B., Kroesen A.J., Buhr H.J., Blaut M., Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls, Scand J Gastroenterol, 37, pp. 1034-1041, (2002)

[6]

Chapman R.W., Selby W.S., Jewell D.P., Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis, Gut, 27, pp. 1210-1212, (1986)

[7]

Mantzaris G.J., Hatzis A., Kontogiannis P., Triadaphyllou G., Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis, Am J Gastroenterol, 89, pp. 43-46, (1994)

[8]

Mantzaris G.J., Petraki K., Archavlis E., Et al., A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis, Scand J Gastroenterol, 36, pp. 971-974, (2001)

[9]

Lobo A.J., Burke D.A., Sobala G.M., Axon A.T., Oral tobramycin in ulcerative colitis: Effect on maintenance of remission, Aliment Pharmacol Ther, 7, pp. 155-158, (1993)

[10]

Guslandi M., Petrone M.C., Testoni P.A., Rifaximin for active ulcerative colitis, Inflamm Bowel Dis, 12, (2006)

← 1 2 3 4 5 6 →